CCCC

C4 Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · SIC 2836CIK 1662579Held by 4 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$36.0M

Net Income FY2025

$(105.0M)

EPS (Basic, as reported)

$-1.27

Net Margin FY2025

-292.1%

ROE FY2025

-40.9%

Total Equity

$257.0M

Shares Out

123M

Business description

C4 Therapeutics, Inc. — Biological Products, (No Diagnostic Substances). Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2019–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 46 → 36 -5.9% CAGR

Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue——4631213636

Research & development(48)(78)(95)(118)(118)(111)(104)

General & administrative(9)(15)(33)(43)(42)(42)(36)

Total operating expenses(57)(94)(128)(161)(160)(155)(151)

Operating income(35)(60)(82)(130)(139)(120)(115)

Other income (expense), net2(7)(2)181410

Pre-tax income(33)(67)(84)(128)(131)(105)(105)

Income tax expense(1)(1)00(1)00

Net income(34)(66)(84)(128)(132)(105)(105)

EPS — basic($31.03)($5.83)($1.82)($2.62)($2.67)($1.52)($1.27)

EPS — diluted——($1.82)($2.62)($2.67)($1.52)($1.27)

Shares outstanding — basic (M)——4649506983

Shares outstanding — diluted (M)——4649506983

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.